Davis Polk advised Novo Nordisk on the deal while Goodwin Procter represented Forma Therapeutics. Novo Nordisk announced its approximately $1.1 billion acquisition of Forma Therapeutics. Under the...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here